Kadimastem and NLS Pharmaceutics Announce Effectiveness of SEC Registration Statement in Connection with Proposed Merger
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 10 2025
0mins
Should l Buy ?
Source: PRnewswire
Merger Announcement: NLS Pharmaceutics Ltd and Kadimastem Ltd have announced that the SEC has declared effective their registration statement related to their merger, which will create a new entity called NewCelX Ltd.
Significance of SEC Approval: The effectiveness of the SEC registration marks a significant milestone in the merger process, as stated by the CEOs of both companies.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
